Summary:
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or risperidone).
Qualified Participants Must:
• Not of childbearing potential if female
•
Be between 18 and 65 years of age, inclusive
•
Have a current diagnosis of schizophrenia
•
Be in need of anti-psychotic treatment and are currently receiving a stable dose
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.